author-photo

Marcus P. Kelly

Regeneron

10

Papers

123

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

2019 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (39)
Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 1777: REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts

2018 Molecular Pharmaceutics
Show All
- Source
- Cite
- Save
Citations (4)
Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

2017 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (54)
Preclinical activity of the novel anti-Prolactin Receptor (PRLR) antibody drug-conjugate REGN2878-DM1 in PRLR positive breast cancers

2017 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (11)
Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)